VARILRIX®

Category: Tag:

Description

VARILRIX® (varicella virus vaccine, live, attenuated (Oka-strain)) is a live-attenuated varicella vaccine which contains the Oka-strain of the attenuated varicella-zoster virus.

VARILRIX® (varicella virus vaccine, live, attenuated (Oka-strain)) is indicated for:

  • the active immunization against varicella of healthy subjects from 12 months of age and up.
  • the active immunization against varicella of susceptible high risk patients and their susceptible healthy close contacts.

Immunization Guideline

  • Children (12 months to 12 years of age, inclusive) should receive 2 doses (0.5 mL each) of VARILRIX® to ensure optimal protection against varicella with a minimum interval of 6 weeks between doses.
  • Adolescents and adults (13 years of age and older) should receive two 0.5 mL doses with a minimum interval of 6 weeks between doses.
  • For high risk patients additional doses of vaccine may be required.

Administration
VARILRIX® (varicella virus vaccine, live, attenuated (Oka-strain)) should be administered by subcutaneous injection in the deltoid region. VARILRIX® must not be administered intravascularly or intradermally.

Additional information

Contraindications

Contraindicated in subjects having shown signs of hypersensitivity after a previous administration of varicella vaccine dose, including anaphylactic reaction, subjects with known hypersensitivity to neomycin or any component of the vaccine. A history of contact dermatitis to neomycin is not a contraindication. The administration of VARILRIX should be postponed in subjects suffering from acute severe febrile illness. In healthy subjects the presence of a minor infection, however, is not a contraindication for vaccination.

country-of-manufacture

Belgium

manufacturer

GlaxoSmithKline

package-size

1 Dose

pharmaceutical-form

Lyophilized

preservative

None

route-of-administration

Subcutaneous

vaccine-type

chickenpox